<DOC>
	<DOCNO>NCT02115594</DOCNO>
	<brief_summary>Preclinical data demonstrate entinostat ( SNDX-275 ) enhance fulvestrant sensitivity hormone receptor-positive breast cancer animal model . The addition entinostat fulvestrant provide clinical benefit patient locally advance metastatic breast compare fulvestrant plus placebo . Also , base previous data , patient expose entinostat demonstrate elevate level protein lysine acetylation improve efficacy outcome .</brief_summary>
	<brief_title>Phase 2 Study Fulvestrant With Without Entinostat Postmenopausal Women With ER+ Advanced Breast Cancer</brief_title>
	<detailed_description>Entinostat ( SNDX-275 ) inhibit mechanisms resistance hormone therapy breast cancer ( BC ) cell , thereby prolong sensitivity cell fulvestrant . Preclinical data demonstrate entinostat enhance fulvestrant sensitivity hormone receptor-positive BC animal model . Thus , hypothesize addition entinostat fulvestrant provide clinical benefit patient locally advance metastatic BC compare fulvestrant plus placebo . Preliminary data Phase 2 Study SNDX-275-0301 suggest patient high level protein lysine acetylation receive entinostat exemestane potentially improve clinical outcome ( e.g. , PFS , OS ) compare patient low level protein lysine acetylation . Thus , hypothesize patient expose entinostat demonstrate elevate level protein lysine acetylation improve efficacy outcome .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
	<criteria>Patient female : Postmenopausal OR Pre/perimenopausal : Received least one prior hormone therapy combination luteinizing hormonereleasing hormone ( LHRH ) agonist prior study entry . Initiated LHRH agonist least 28 day prior study entry . Demonstrated ovarian estradiol suppression , define estradiol level within postmenopausal range per institutional guideline , within 28 day immediately prior study entry Patient histologically cytologically confirm ER+ and/or progesterone receptorpositive ( PR+ ) BC initial diagnosis subsequent biopsy . With regard hormone receptor status , stain ≥1 % cell consider positive . Receptor status may determine time prior randomization site ( i.e. , primary , recurrent , metastatic ) Patient experience PD within 28 day initiate study treatment deem eligible treatment fulvestrant Patient evidence locally advance metastatic disease , base imaging study ( bone scan , CT , MRI ) within 28 day initiate study treatment Patient complete prior radiotherapy ≥2 week prior receive first dose study treatment recover radiationrelated toxicity Patient may receive 1 prior chemotherapy regimen metastatic disease provide treatment complete ≥3 week prior randomization . Prior chemotherapy adjuvant neoadjuvant setting also allow Patient willing able provide assist study personnel access slide prior biopsy Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patient follow laboratory parameter : a. Hemoglobin ( Hgb ) ≥9.0 g/dL ; unsupported platelet count ≥100×10P9P/L ; absolute neutrophil count ( ANC ) ≥1.5×10P9P/L without use hematopoietic growth factor ; b. Creatinine ≤2.0 mg/dL ; c. Total bilirubin &lt; 1.5 x institutional upper limit normal ( ≤3 mg/dL case Gilbert 's syndrome ) ; d. Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2 x institutional upper limit normal ; unless elevation due metastatic disease liver , case ALT AST must within 5.0 x institutional upper limit normal Patient able swallow tablet Patient able understand give write informed consent comply study procedure Patient rapidly progressive lifethreatening metastasis ( visceral crisis ) Patient HER2positive ( HER2+ ) disease , define 2013 American Society Clinical Oncology ( ASCO ) /College American Pathologists ( CAP ) recommendation HER2 test BC ( see http : //www.asco.org/qualityguidelines/recommendationshumanepidermalgrowthfactorreceptor2testingbreastcancer ) , unknown HER2 status Patient previously receive treatment entinostat HDAC inhibitor , include valproic acid Patient previous treatment fulvestrant selective estrogen receptor downregulator ( SERD ) metastatic setting ; treatment may give adjuvant set Patient allergy benzamide inactive component study drug Patient history allergy active inactive ingredient fulvestrant Patient concomitant medical condition precludes adequate study treatment compliance assessment , increase patient risk , opinion Investigator , limit : 1 . Myocardial infarction arterial thromboembolic event within 6 month prior Baseline severe unstable angina , New York Heart Association ( NYHA ) Class III IV disease ( see Appendix 2 ) , QTc interval &gt; 470 msec . 2 . Uncontrolled heart failure hypertension , uncontrolled diabetes mellitus , uncontrolled systemic infection 3 . Another active cancer ( exclude adequately treat basal cell carcinoma cervical intraepithelial neoplasia [ CIN ] / cervical carcinoma situ melanoma situ ) . Prior history cancer allow , long active disease within prior 5 year Patient currently receive treatment agent list prohibited medication list valproic acid systemic cancer agent Patient initiate oral bisphosphonates within 7 day prior study drug Patient moderate severe hepatic impairment ( i.e. , ChildPugh score B C ) Patient brain leptomeningeal metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>estrogen receptor</keyword>
	<keyword>Histone Deacetylase Inhibitors</keyword>
	<keyword>Histone Deacetylases</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>selective estrogen receptor modulator</keyword>
	<keyword>estrogen receptor modulator , selective</keyword>
	<keyword>Estrogen receptor modulators , selective</keyword>
</DOC>